Clonal Evolutionary Analysis during HER2 Blockade in HER2-Positive Inflammatory Breast Cancer: A Phase II Open-Label Clinical Trial of Afatinib +/- Vinorelbine.

<h4>Background</h4>Inflammatory breast cancer (IBC) is a rare, aggressive form of breast cancer associated with HER2 amplification, with high risk of metastasis and an estimated median survival of 2.9 y. We performed an open-label, single-arm phase II clinical trial (ClinicalTrials.gov NCT01325428)...

Cijeli opis

Bibliografski detalji

Glavni autori:	Gerald Goh, Ramona Schmid, Kelly Guiver, Wichit Arpornwirat, Imjai Chitapanarux, Vinod Ganju, Seock-Ah Im, Sung-Bae Kim, Arunee Dechaphunkul, Jedzada Maneechavakajorn, Neil Spector, Thomas Yau, Mehdi Afrit, Slim Ben Ahmed, Stephen R Johnston, Neil Gibson, Martina Uttenreuther-Fischer, Javier Herrero, Charles Swanton
Format:	Artigo
Jezik:	Inglês
Izdano:	Public Library of Science (PLoS) 2016-12-01
Serija:	PLoS Medicine
Online pristup:	https://doi.org/10.1371/journal.pmed.1002136
Oznake:	Dodaj oznaku Bez oznaka, Budi prvi tko označuje ovaj zapis!